Benevolent News Hub

BenevolentAI announces participation in upcoming investor conferences
BenevolentAI announces its participation at two upcoming biotech and healthcare investor conferences hosted by Goldman Sachs and Morgan Stanley.
Jun 10, 2022
BenevolentAI Announces Board Changes
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
May 25, 2022
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
BenevolentAI Begins Trading On Euronext Amsterdam
BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.
Apr 25, 2022
BenevolentAI · AI-Enabled Drug Discovery
Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.
Apr 25, 2022
BenevolentAI joins the World Economic Forum’s Global Innovators Community
BenevolentAI joins the World Economic Forum’s Global Innovators Community to help ethically deploy AI to create a more sustainable, inclusive and resilient world.
Apr 21, 2022
DNDi and BenevolentAI collaborate to accelerate life-saving drug discovery research in dengue
BenevolentAI and Drugs for Neglected Disease initiative (DNDi) enter a joint research project to use AI to accelerate drug discovery research in dengue, a climate-sensitive neglected disease.
Apr 20, 2022
RECOVERY trial results demonstrate baricitinib reduces deaths in hospitalised COVID-19 patients
RECOVERY trial data show Eli Lilly-owned baricitinib reduces death in patients hospitalised with COVID-19, further validating BenevolentAI’s initial AI-derived hypothesis.
Mar 4, 2022
BenevolentAI partners with the Helix Group at Stanford University to advance research on AI-driven drug discovery
BenevolentAI and the Helix Group — led by Prof. Russ Altman — partner on research into more effective methods to extract knowledge from biological information.
Feb 3, 2022